Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2017’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)

The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects

The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AbGenomics International Inc

Allergan Plc

Amunix Operating Inc

AnaptysBio Inc

apceth Biopharma GmbH

Aptevo Therapeutics Inc

arGEN-X BV

Athersys Inc

Bellicum Pharmaceuticals Inc

Bio-Cancer Treatment International Ltd

Biogen Inc

Bristol-Myers Squibb Company

Capricor Therapeutics Inc

Cell2B Advanced Therapeutics SA

Cellect Biomed Ltd

Commence Bio Inc

Cynata Therapeutics Ltd

Cytodyn Inc

Escape Therapeutics Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Generon (Shanghai) Corp Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Incyte Corp

Jazz Pharmaceuticals Plc

Johnson & Johnson

Kadmon Corp LLC

Kamada Ltd

Kiadis Pharma NV

Kymab Ltd

Kyorin Pharmaceutical Co Ltd

MacroGenics Inc

Mallinckrodt Plc

Mesoblast Ltd

Millennium Pharmaceuticals Inc

Nohla Therapeutics Inc

Novartis AG

OncoImmune Inc

Pfizer Inc

Pharmicell Co Ltd

REGiMMUNE Corp

Sanofi

Sarepta Therapeutics Inc

Seattle Genetics Inc

Seres Therapeutics Inc

Sigmoid Pharma Ltd

Synedgen Inc

Takeda Pharmaceutical Company Ltd

Targazyme Inc

TC BioPharm Ltd

TxCell SA

United BioPharma Inc

Vault Pharma Inc

VBI Vaccines Inc

Xenikos BV

XL-protein GmbH

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Graft Versus Host Disease (GVHD) - Overview 6

Graft Versus Host Disease (GVHD) - Therapeutics Development 7

Graft Versus Host Disease (GVHD) - Therapeutics Assessment 23

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 35

Graft Versus Host Disease (GVHD) - Drug Profiles 62

Graft Versus Host Disease (GVHD) - Dormant Projects 389

Graft Versus Host Disease (GVHD) - Discontinued Products 393

Graft Versus Host Disease (GVHD) - Product Development Milestones 394

Appendix 404

List of Tables

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by AbbVie Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by AbGenomics International Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Allergan Plc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Amunix Operating Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by AnaptysBio Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by apceth Biopharma GmbH, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Aptevo Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by arGEN-X BV, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Athersys Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Bio-Cancer Treatment International Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Biogen Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Bristol-Myers Squibb Company, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Capricor Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Cell2B Advanced Therapeutics SA, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Cellect Biomed Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Commence Bio Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Cynata Therapeutics Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Cytodyn Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Escape Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Fate Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Generon (Shanghai) Corp Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Gilead Sciences Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by GlaxoSmithKline Plc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Incyte Corp, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Jazz Pharmaceuticals Plc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Johnson & Johnson, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Kadmon Corp LLC, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Kamada Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Kiadis Pharma NV, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Kymab Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by MacroGenics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Mallinckrodt Plc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Mesoblast Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Nohla Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Novartis AG, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by OncoImmune Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Pfizer Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Pharmicell Co Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by REGiMMUNE Corp, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Sanofi, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Sarepta Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Seattle Genetics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Seres Therapeutics Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Sigmoid Pharma Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Synedgen Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Targazyme Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by TC BioPharm Ltd, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by TxCell SA, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by United BioPharma Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Vault Pharma Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by VBI Vaccines Inc, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by Xenikos BV, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by XL-protein GmbH, H2 2017

Graft Versus Host Disease (GVHD) – Pipeline by ZIOPHARM Oncology Inc, H2 2017

Graft Versus Host Disease (GVHD) – Dormant Projects, H2 2017

Graft Versus Host Disease (GVHD) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Graft Versus Host Disease (GVHD) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Graft Versus Host Disease (GVHD) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Graft Versus Host Disease (GVHD) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports